Notch Therapeutics

Notch Therapeutics

Edit info

  • Founded: 2018
  • Location: Toronto, ON
  • Employee range: 50 - 200
  • Clinical stage: Clin0
  • Therapy area: Hematologic malignancies
  • Drug types: ONC, IMM
  • Lead product: Cytotoxic T Cells
  • Funding: $85M A Feb 2021


notchtx.com

linkedin.com

job board


Drug notes:

Also Clin0 Solid & hematologic malignancies; T Regulatory Cells Clin0 autoimmune diseases; undisclosed programs RD undisclosed

About:

Notch Therapeutics is manufacturing therapeutic T cells from pluripotent stem cells using their understanding of Notch signaling. Notch genes encode a family of receptors that drive cell fate decisions by binding ligands and transmitting signals between adjacent cells. By uncovering that Notch signaling is important for T cell development, Notch Therapeutics is taking an engineering approach to solve major bottlenecks in iPSC-derived T cell manufacturing. In this way, exploiting the Notch signaling pathway enables T cells to be matured without the need for a thymus. The advantage of starting with iPSCs which can be cultured at massive scale means that Notch has a potentially limitless source of starting materials for the production of therapeutically relevant cells.

Jobs:

Notch Therapeutics
Research Associate I, Preclinical Sciences
Seattle, Washington|17 days ago
Apply


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com